Furthermore, clinical trials undertaken with prostate cancer patients who are carriers of a mutant PALB2 have demonstrated a positive response to Olaparib treatments, particularly for patients with resistance to treatment [33,48]. The gene discussed is PALB2; the disease is Familial prostate cancer.